🇺🇸 FDA
Patent

US 9266856

AMPK—activating heterocyclic compounds and methods for using the same

granted A61PA61P1/04A61P1/14

Quick answer

US patent 9266856 (AMPK—activating heterocyclic compounds and methods for using the same) held by Rigel Pharmaceuticals, Inc. expires Mon Feb 18 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Rigel Pharmaceuticals, Inc.
Grant date
Tue Feb 23 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 18 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
30
CPC classes
A61P, A61P1/04, A61P1/14, A61P1/16, A61P1/18